RxDoctor Payments Data

Kathleen Linke, PA

Physician Assistant · Hemet, CANPI 1265883649

Payments from drug & device makers

$10,244in general payments, 2019–2025

Across 508 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$738
  • Gilead$674
  • Pfizer$583
  • Johnson & Johnson$477
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$10,11899%
  • Education$541%
  • Gifts$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,244 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$38,721
Medicare patients
247
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase57$255,449
SucraidSacrosidase14$194,282
LinzessLinaclotide81$88,572
XifaxanRifaximin14$40,729
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C196$25,772
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates289$16,862
Dexlansoprazole DrDexlansoprazole20$6,957
Mesalamine12$6,851
Rabeprazole Sodium158$4,349
Cholestyramine LightCholestyramine29$4,137
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,139
Pantoprazole Sodium212$1,866
Lansoprazole24$897
Omeprazole66$895
PrevaliteCholestyramine13$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$4,028$344,021138 claims
QOL Medical, LLCSucraid$169$194,28214 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,222$66,501210 claims
Braintree Laboratories, Inc.Sutab$102$2,13913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →